Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
1.447
-0.003 (-0.23%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

The company’s development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older.

In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection.

Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus.

The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023.

Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Barinthus Biotherapeutics plc
Barinthus Biotherapeutics logo
Country United Kingdom
Founded 2016
IPO Date Apr 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 130
CEO William Enright

Contact Details

Address:
Zeus Building, Unit 6-10
Didcot, OX11 0DF
United Kingdom
Phone 44 1865 818 808
Website barinthusbio.com

Stock Details

Ticker Symbol BRNS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001828185
ISIN Number US91864C1071
SIC Code 2834

Key Executives

Name Position
William J. Enright MBA Chief Executive Officer and Director
Graham Griffiths Chief Operating Officer
Dr. Nadege Pelletier Ph.D. Chief Scientific Officer
Sarah Gilbert Co-Founder
Adrian Hill Ph.D. Co-Founder and Scientific Advisor
Gemma Brown Chief Financial Officer and Company Secretary
Elizabeth Eagling-Vose M.B.A. Head of Clinical Operations
Bernie McDonald Head of IP
Geoffrey Lynn Senior Vice President of Synthetic Immunotherapies
Dr. Leon Hooftman M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 1, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 15, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 5, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jun 12, 2024 8-K Current Report
Jun 6, 2024 8-K Current Report
May 15, 2024 8-K Current Report
May 14, 2024 8-K/A [Amend] Current report
May 13, 2024 10-Q Quarterly Report